StudyFinder
Clear

Search Results Within Category "Heart and Vascular"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Heart and Vascular"

Advanced Heart Failure and Transplant Angina Arrhythmias Cardiac Rehabilitation Coronary Artery Disease Heart Structure Defect/Congenital Heart Defect Heart Valve Research Hypertension LVAD Peripheral Artery Disease Preventative Cardiology Pulmonary Embolism
3 Study Matches

Home-based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation (MOVE-LVAD II)

This study is looking at whether a home-based exercise program, supported by mobile technology (such as a smartphone app, wearable device, or remote monitoring tools), can help people who have received a HeartMate 3 (HM3) LVAD become more active, stronger, and healthier after surgery.

Contact(s):

Joshua Joven - jjoven2@hfhs.org

Principal Investigator: Jennifer Cowger
Principal Investigator ID: jcowger1@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: II
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
This study is for adults who have recently received their first HeartMate 3 LVAD, are able to get around independently, have a smartphone, and are living at home (or will be soon after discharge). These requirements help ensure participants can safely take part in the home-based exercise program and use the mobile technology involved in the study.
Exclusion Criteria:
A person cannot take part in the study if they have other serious health problems that would make exercise unsafe or not possible. This includes major movement or nerve problems (like severe joint or brain/nerve conditions), worsening or unstable heart failure, dangerous or poorly controlled heart rhythms, or chest pain caused by reduced blood flow to the heart (unstable angina).
Conditions: Heart Failure
Keywords: Exercise, Heart Failure, Heart Mate III, Heart Pump, HMIII, Left Ventricular Assist Device, LVAD

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The DAL-302 (dal-GenE-2) trial

This research study is testing whether a medication called dalcetrapib can help lower the risk of future heart attacks in people who were recently hospitalized for acute coronary syndrome and have a certain genetic profile. The study compares dalcetrapib to a placebo to see if personalized, genetics-based treatment can better prevent serious heart problems.

Contact(s):

Jodi Carter - GeneralCardiologyResearch@hfhs.org

Principal Investigator: Khaled Nour
Principal Investigator ID: knour1@hfhs.org
Sex: Male or Female
Age: 18 years and over
Phase: III
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• Age 45 or older
• Heart Attack within the last 90 days
• Must have AA genotype to move forward in study (we will perform the test for this at day 1
Exclusion Criteria:

• Severe heart failure
• Severe kidney failure
• Received bypass surgery since the recent heart attack
Interventions: Drug/Device: Dalcetrapib
Conditions: Heart Attack
Keywords: Cholesterol, Heart Attack, Myocardial Infarction

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov

Randomized Evaluation of Bromocriptine in Myocardial Recovery Therapy (REBIRTH) for Peripartum Cardiomyopathy

Peripartum cardiomyopathy (PPCM) is a rare type of heart failure that can happen during the last month of pregnancy or within five months after giving birth, causing the heart to weaken and not pump blood well. Many women improve with heart failure treatment. This study is testing whether bromocriptine, a drug approved in the U.S. for other conditions but not PPCM, can help improve heart function in women recently diagnosed with PPCM.

Contact(s):

Jodi Carter - Jcarte23@hfhs.org

Principal Investigator: Ryhm Radjef
Principal Investigator ID: rradjef1@hfhs.org
Sex: Female
Age: 18 years and over
Phase: IV
Healthy Volunteers:
This study is NOT accepting healthy volunteers
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:

• New diagnosis of peripartum cardiomyopathy
• Post-delivery and within the first 5 months post-partum
Exclusion Criteria:

• Previous diagnosis of heart disease (prior to pregnancy)
Interventions: Drug/Device: Bromocriptine
Conditions: Peripartum or Postpartum Cardiomyopathy
Keywords: cardiomyopathy, heart failure, Peripartum, postpartum

Further Actions

I'm interested
Share via email
See this study on ClinicalTrials.gov